World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
45
Citations
11173
World Ranking
6826
National Ranking
2954

Best Publications

  • Short Sleep Duration as a Risk Factor for Hypertension Analyses of the First National Health and Nutrition Examination Survey

    James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs

  • Sleep Duration as a Risk Factor for Diabetes Incidence in a Large US Sample

    James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs

  • Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes

    Gary D. Foster;Mark H. Sanders;Richard Millman;Gary Zammit

  • Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.

    A Blackman;G D Foster;G Zammit;R Rosenberg

  • An efficacy, safety, and dose–response study of Ramelteon in patients with chronic primary insomnia

    Milton Erman;David Seiden;Gary Zammit;Stephen Sainati

  • Earlier Parental Set Bedtimes as a Protective Factor Against Depression and Suicidal Ideation

    James E. Gangwisch;Lindsay A. Babiss;Dolores Malaspina;J. Blake Turner

  • Long-Term Effect of Weight Loss on Obstructive Sleep Apnea Severity in Obese Patients with Type 2 Diabetes

    Samuel T Kuna;Samuel T Kuna;David M Reboussin;Kelley E Borradaile;Mark H Sanders

  • Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health.

    James E. Gangwisch;Dolores Malaspina;Lindsay A. Babiss;Mark G. Opler

  • Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample.

    James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs;Ruud M. Buijs

  • Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

    Unknown

  • Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study

    Andrew D. Krystal;Milton Erman;Gary K. Zammit;C. Soubrane

  • Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.

    Gary Zammit;Milton Erman;Sherry Wang-Weigand;Stephen Sainati

  • A new questionnaire to detect sleep disorders.

    Thomas Roth;Gary Zammit;Clete Kushida;Karl Doghramji

  • Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.

    Sheldon Preskorn;Matthew Macaluso;Do Vishaal Mehra;Gary Zammit

  • Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial

    Russell Rosenberg;Patricia Murphy;Gary Zammit;David Mayleben

  • Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.

    Gary K. Zammit;Louis J. McNabb;Judy Caron;David A. Amato

  • Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.

    Paula K Schweitzer;Russell Rosenberg;Gary K Zammit;Mark Gotfried

  • Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.

    Patricia Murphy;Margaret Moline;David Mayleben;Russell Rosenberg

  • Hypoglossal nerve stimulation improves obstructive sleep apnea: 12-month outcomes.

    Eric J. Kezirian;George S. Goding;Atul Malhotra;Fergal J. O'Donoghue

  • Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.

    Mikko Kärppä;Jane Yardley;Kate Pinner;Gleb Filippov

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: